**Case Report**

**Reactivation of Epstein–Barr Virus Presenting as Massive Splenomegaly after Initiation of Golimumab Treatment**

Anthony J. Febres-Aldana,1 Christopher A. Febres-Aldana,2 Kathrin Dvir,1 Gliceida Galarza-Fortuna,1 Michael Schwartz,3 Ana M. Medina,2,4 and Vathany Sriganeshan2,4

1Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
2Arkadi M. Rywlin Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
3Division of Oncology, Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA
4Herbert Wertheim College of Medicine, Florida International University, Miami 33199, FL, USA

Correspondence should be addressed to Anthony J. Febres-Aldana; anthony.febres@msmc.com

Received 31 January 2020; Accepted 13 March 2020; Published 10 April 2020

Academic Editor: Kiyotaka Kawauchi

Copyright © 2020 Anthony J. Febres-Aldana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Epstein–Barr virus infection is most commonly asymptomatic in the acute setting, where the end result of infection is the adoption of a viral latency phenotype. The virus can reactivate later in life leading to the abnormal proliferation of the infected B, T, or NK cells. Hereby, we report a 71-year-old female with seronegative rheumatoid arthritis who presented with massive splenomegaly, pancytopenia, and positivization of antibodies against double-stranded deoxyribonucleic acid (dsDNA) after initiation of the anti-tumor necrosis factor (TNF) golimumab. The diagnosis of EBV-associated lymphoproliferative disorder (LPD) was demonstrated by elevation of the plasmatic EBV viral load. Withdrawal of the anti-TNF and treatment with the anti-CD20 antibody rituximab were able to revert the clinical abnormalities. EBV-associated LPDs are described after initiation of other anti-TNF agents, such as infliximab, but no reports of golimumab-associated EBV LPD are found in the literature. The mechanisms for this occurrence are not clear, but these are known to involve expression of a panel of viral proteins specific to the viral latency phenotypes.

1. Introduction

Epstein–Barr virus (EBV) is a gamma-herpesvirus that prevails in over 90% of the population. The primary infection is most commonly asymptomatic, and it may manifest later in adulthood [1]. Although B cells are the main target of EBV due to its tropism for CD21+ cells, the virus can also infect T cells, NK cells, and less frequently epithelial cells. The virus may remain dormant in these cells and may reactivate later in adulthood through mechanisms that are poorly understood. This article reports the occurrence of EBV reactivation presenting as a biclonal lymphoproliferative disorder (LPD) in a patient with rheumatoid arthritis, triggered by initiating therapy with the anti-tumor necrosis factor (TNF) golimumab.

2. Case Presentation

A 71-year-old woman presented to our emergency department because of left-sided abdominal pain, fatigue, anorexia, early satiety, and low-grade fever for two weeks. She carried the diagnosis of seronegative rheumatoid arthritis (RA) based on the presence of inflammatory arthritis with negative anticitrullinated peptides antibodies (ACPA) and negative rheumatoid factors (RF). Her inflammatory symptoms were initially controlled on etanercept, but the medication was switched to tofacitinib a year prior to presentation due to chronic cough. However, tofacitinib triggered episodes of elevated blood pressure, dizziness, and headaches, so golimumab was started instead three months before. While on golimumab, her symptoms related to the
arthriti
case reports in hematology
the lymphocytosis was composed mainly of CD4+ T-lym-
reticulin fibrosis. Flow cytometry of the blood showed that
trilineage hematopoiesis, erythroid hyperplasia, and mild
biopsy revealed a hypercellular bone marrow for age with
an interferon-
c tomography (PET) scan. N_he levels of C3 were 70mg/L, and
hypoattenuation and normal uptake on positron emission
presence of massive splenomegaly (Figure 1), with focal
the patient was admitted to the medical ward. An ab-
positiveat1:20.Otherantinuclearantibodieswerenegative.
deroxyribonucleic acid (DNA) antibody determined by the
indirect immunofluorescence assay was positive at 1: 20. Other antinuclear antibodies were negative.
psoriasis.
In contrast to her sister, the patient never presented
symptoms consistent with inflammatory bowel disease or
essential thrombocythemia. Her family history was remarkable for a sister with in-
back from South Africa where she visited only urban areas.
overload remained negative. Anti-dsDNA persisted positive with
1: 80 dilution.
3. Discussion
The patient developed an immunodeficiency-associated
(IDA) LPD triggered by reactivation of EBV after initiation
of the anti-tumor necrosis factor (TNF) golimumab. LPD is
an umbrella term that ranges from reactive to monoclonal
lymphoid proliferations with malignant behavior [2], and
this reflects the stage of the EBV replication cycle [3]. Even
though the precise events that lead to the expression of the
viral latency phenotypes are not well defined, these are
identified based on the expression of multiple nuclear an-
tigens (EBNA) and latent membrane proteins (LMP),
proteins that help the virus to evade immune surveillance.
The combination of different isoforms of each of these
proteins and transcripts allows the distinction of at least
three well-defined latency patterns with specific clinical
expressions [3, 4]. The patient’s LPD presentation was
consistent with expression of a latency III phenotype, which
is associated with IDA-LPDs, and it is the most immunono-
genic result of expression of all EBV latency transcripts and
proteins [3]. The restricted expression of EBV-encoded small
RNAs (EBER) or EBNAl corresponds to pattern I latency,
and it occurs in memory B cells. Selected expression of
EBNAl, LMP1, LMP2A and LMP2B, EBERs, and the
BamHI A rightward transcripts (BARTs) defines pattern II
latency. This pattern is seen in germinal center B cells.
Latency III pattern occurs in naïve B cells [3].

Exclusive latency I phenotype occurs in subclinical re-
active lymphoid hyperplasia, Burkitt lymphoma, plasma-
blastic lymphoma, and primary effusion lymphoma.
Coinfection of EBV in latency I pattern with human her-
pesivirus type 8 and human immunodeficiency virus (HIV)
can lead to the development of a monoclonal LPD. Latency
II pattern occurs in otherwise immunocompetent individu-
als who develop EBV-associated Hodgkin lymphoma, T/
NK-cell lymphomas, and follicular T-cell lymphoma [3].
This type of latency also occurs during the hydroa vacci-
formae and severe mosquito bite allergy, both polyclonal
LPDs localized to the skin and with a potential to dissem-
inate as a clone-restricted LPD [5]. Latency III occurs in
the case of EBV-associated diffuse large B-cell lymphoma,
posttransplant lymphoproliferative disorders, immunode-
ficiency-associated LPDs, and iatrogenic LPDs. Expression
of the latency III phenotype is associated with simultaneous
inhibition of apoptosis and progression of the cell cycle to M
phase, with the result of growth arrest and consequent
immortalization of the infected lymphocytes [5].

EBV reactivation can be linked to the use of TNF
blockers [6], with infliximab being the most common culprit
agent in the class [7, 8]. However, the evidence linking the
use of TNF agents as an independent risk factor for the
development of LPDs is nonconclusive, with some cohorts
demonstrating an increased risk for development of lymph-
phomas [9] but others demonstrating a nonsignificant
This discrepancy could be explained by the degree of disease activity of the RA, including history of previously uncontrolled disease before starting the TNF blocker, as RA is associated independently with the development of LPDs, including lymphomas, and the risk seems not to be fully reversed after the use of any of the disease modifying antirheumatic drugs (DMARDs) [12]. In fact, these patients have higher risk for lymphoma development even when on treatment [13]. The disease of our patient presented a low activity based on her symptoms related to the RA at the moment of initiation of golimumab, and the decision to start the biologic agent was driven by the fact that she had poor response to other DAMRDs in the past, including methotrexate (MTX). In regards to those cases that occur in association with reactivation of EBV, this seems to be a rare event and therefore the association is more difficult to determine. This is the first report of a case of an EBV-associated LPD after starting golimumab in a patient who was previously exposed in two separate moments to a Janus Kinase inhibitor and to etanercept and that had clinical reversion after its withdrawal. The regression of the LPD after withdrawal of therapy has also been described for cases of RA-associated EBV-lymphomas in patients on MTX [14], with the presence of EBV in the tumor being a predictor of the occurrence of this phenomenon. It is unlikely that tofacitinib had played a role in this case as the agent has not proven to alter EBV or CMV viral loads [15]. Of note, no studies evaluating the effect of tofacitinib on EBV viral load in patients with RA have been performed to date and the data available come from patients with psoriasis, disease which has no intrinsic association with the development of lymphomas. One potential contributing factor to this clinical presentation was the history of long-standing use of etanercept by the patient, which stopped months before initiating golimumab, as the long-term side effects of use of these agents are not predictable [16].

For the diagnosis, the EBV load in peripheral blood mononuclear cells (PBMC) can aid to determine when the LPD is driven by EBV reactivation. While an EBV viral load above 500 copies per 500 ng determines an association of EBV reactivation with the LPD [17], the patients with RA tend to have viral loads that are around 10-fold higher than those patients without the disease [18]. The use of anti-TNF therapy by itself is not associated with an increased EBV load [19, 20]. Therefore, the kinetics of the EBV viral load has a better predictive value for the diagnosis of EBV-associated LPDs when the PBMC EBV viral load is monitored, namely in patients who are allograft or hematopoietic stem cell transplant (HSCT) recipients [21]. B-cell receptor (BCR) rearrangement studies are useful in these cases as well as they allow the identification of clonal nature of the LPD, as most EBV-related LPDs are B cells in origin [2]. Except for the reactive lymphoid proliferations, EBV-associated LPDs are
most commonly monoclonal. Oligoclonal or polyclonal LPDs are less commonly seen.

Expression of viral proteins during EBV reactivation may result in the cross-activation of self-reactive T or B cells, a phenomenon termed antigenic mimicry. For example, the viral latency protein EBNA-1 can lead to the formation of antibodies that are able to bind dsDNA [22]. High-titer antinuclear antibodies (ANA) are also associated with the presence of IgM or IgG against the EBV VCA [23] although our patient had undetectable ANA. Whether these antibodies carry the same immunologic and clinical significance as in systemic lupus erythematosus (SLE) is unknown, and this support the theory that dsDNA antibodies belong to a continuum where low avidity dsDNA antibodies can develop spontaneously and can be found in some healthy individuals while higher avidity antibodies are more specific for patients with clinical expression of SLE [24]. The occurrence of anti-dsDNA during anti-TNF therapy has been shown [25].

Treatment of EBV-associated LPDs depends on the patient’s immune status and tumor pathology. Overall, in immunosuppressed patients and as exemplified in this case, withdrawal of the immunosuppressive insult is the mainstay for treatment; if this fails, rituximab is a potential addition to the treatment of B-cell LPDs in this setting [5]. The decision to add chemotherapy depends on the initial histologic diagnosis, with most high-grade B-cell lymphomas requiring combination regimens with addition of rituximab [5]. Furthermore, patients who fail an initial therapeutic trial with withdrawal of the drug and use of rituximab may require antiviral therapy in addition to chemotherapy, but this approach is still under investigation [5]. Recommendations for cases of iatrogenic EBV-associated LPDs after initiation of drugs are less well defined, but withdrawal of the trigger

Figure 3: Flow cytometry (a) and B-cell immunoglobulin gene rearrangement studies (b) demonstrating the clonal nature of the golimumab-induced lymphoproliferative disorder. An abnormal population of B cells (CD-45+, CD-19+) with a dim expression of surface kappa light chain and negative for lambda light chain. B electropherograms of fluorescently labeled PCR products detected by capillary gel electrophoresis showing polyclonality, Gaussian distribution of products, using the BIOMED-2 primer sets IGH FR1, FR2, FR3, IGK VJ, and IGK VKde. Two broad dominant peaks (234.06 bp and 285.08 bp) were identified with the IGK VKde primer set, which targets the deleting element of the kappa light chain. This result is consistent with the presence of two B-cell clones.
medication alone can reverse them. Hematopoietic stem cell transplantation in addition to immunochemotherapy is an effective approach for either CAEBV or HLH with malignant characteristics [26]. Those patients with concomitant HIV infection require the use of highly active antiretroviral treatment [5]. More specific therapies targeting EBV infected cells are under development, and these strategies include the use of gene therapy to enhance the sensitivity of EBV in latent phase to antiviral agents or to induce apoptosis of EBV infected cells, and infusion of autologous cytotoxic T lymphocytes specific against EBV latency proteins (CMD-003, baltaeleucel-T) [27]. Another promising approach is the induction of the EBV lytic cycle, which increases sensitivity to antiviral medication, accomplished with the use of chemotherapy [27].

4. Conclusion

This case demonstrates that reactivation of EBV occurs in those patients with chronic immunologic derangements after initiation of immunomodulatory therapy. Even though parts of the molecular events related to EBV latency are known, the specific mechanisms through which anti-TNF agents are able to trigger the development of LPDs are not completely understood. Based on the current evidence, use of the EBV viral load in conjunction with flow cytometry analysis are helpful tools in detecting those patients with potentially curable diseases.

Consent

Written informed consent was obtained from the patient.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

AF and CF were in charge of conceptualization, data curation, methodology, project administration, and writing original draft and the definite version of the manuscript. KD and GG helped for resources and visualization. MS gave original draft and the definite version of the manuscript. KD supervised, and validated and GG helped for resources and visualization. MS gave original draft and the definite version of the manuscript. KD curation, methodology, project administration, and writing AF and CF were in change of conceptualization, data analysis are helpful tools in detecting those patients with potentially curable diseases.

References

[1] A. Norwalk and M. Green, “Epstein-Barr virus,” in Diagnostic Microbial Immunocompromised Host, pp. 127–134, American Society for Microbiology (ASM), Washington, DC, USA, 2nd edition, 2015.
[2] J. J. M. van Dongen, A. W. Langerak, M. Brüggemann et al., "Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936," Leukemia, vol. 17, no. 12, pp. 2257–2317, 2003.
[3] S. A. Rezk, X. Zhao, and L. M. Weiss, “Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update,” Human Pathology, vol. 79, pp. 18–41, 2018.
[4] K. Ohshima, H. Kimura, T. Yoshino et al., “Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD,” Pathology International, vol. 58, no. 4, pp. 209–217, 2008.
[5] E. Tse and Y.-L. Kwong, “Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target,” Experimental & Molecular Medicine, vol. 47, no. 1, e136, 2015.
[6] M. I. Shale, C. H. Seow, C. S. Coffin, G. G. Kaplan, R. Panaccione, and S. Ghosh, “Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 31, no. 1, pp. 20–34, 2010.
[7] W. Sondermann, H. A. Baba, and A. Köhrer, “Hepatitis due to EBV-reactivation under infliximab in a psoriasis patient,” Dermatologic Therapy, vol. 30, no. 5, p. e12525, 2017.
[8] M. Colaci, M. Sebastiani, G. Sandri, M. Meacci, and C. Ferri, “Epstein-Barr virus reactivation after infliximab in rheumatoid arthritis: a case report,” Case Reports in Infectious Diseases, vol. 2011, Article ID 530568, 3 pages, 2011.
[9] G. S. Calip, P. R. Patel, S. Adimadhyam et al., “Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions,” International Journal of Cancer, vol. 143, no. 5, pp. 1062–1071, 2018.
[10] J. Asking, E. Baekklund, F. Granath et al., “Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register,” Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 648–653, 2009.
[11] F. Wolfe and K. Michaud, “The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation,” Arthritis & Rheumatism, vol. 56, no. 5, pp. 1433–1439, 2007.
[12] E. Baekklund, K. E. Smedby, L.-A. Sutton, J. Asking, and R. Rosenquist, “Lymphoma development in patients with autoimmune and inflammatory disorders - what are the driving forces?” Seminars in Cancer Biology, vol. 24, pp. 61–70, 2014.
[13] X. Mariette, D. Cazals-Hatem, J. Warszawski et al., “Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France,” Blood, vol. 99, no. 11, pp. 3909–3915, 2002.
[14] A. Ichikawa, F. Arakawa, J. Kiyasu et al., “Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression,” European Journal of Haematology, vol. 91, no. 1, pp. 20–28, 2013.
[15] F. Valenzuela, K. A. Papp, D. Pariser et al., “Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis,” BMC Dermatology, vol. 15, no. 1, 2015.
[16] A. Lavagna, M. Bergallo, M. Daperno et al., “Infliximab and the risk of latent viruses reactivation in active Crohn’s disease,” Inflammatory Bowel Diseases, vol. 13, no. 7, pp. 896–902, 2007.
[17] N. Balandraud, J. Roudier, and C. Roudier, “What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?” Seminars in Arthritis and Rheumatism, vol. 34, no. 5, pp. 31–33, 2005.
[18] N. Balandraud, J. B. Meynard, I. Auger et al., “Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase
chain reaction,” *Arthritis & Rheumatism*, vol. 48, no. 5, pp. 1223–1228, 2003.

[19] M. Couderc, S. Payet, C. Henquell, J.-J. Dubost, and M. Soubrier, “TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis,” *Joint Bone Spine*, vol. 77, no. 5, pp. 414–417, 2010.

[20] C. Miceli-Richard, N. Gestermann, C. Amiel et al., “Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies,” *Arthritis Research & Therapy*, vol. 11, no. 3, p. R77, 2009.

[21] H. Kimura and Y.-L. Kwong, “EBV viral loads in diagnosis, monitoring, and response assessment,” *Frontiers in Oncology*, vol. 9, p. 62, 2019.

[22] P. Yadav, H. Tran, R. Ebegbe et al., “Antibodies elicited in response to EBNA-1 may cross-react with dsDNA,” *PLoS One*, vol. 6, Article ID e14488, 2011.

[23] L. Cuomo, M. Cirone, A. O. Di Gregorio et al., “Elevated antinuclear antibodies and altered anti-Epstein-Barr virus immune responses,” *Virus Research*, vol. 195, pp. 95–99, 2015.

[24] O. P. Rekvig and J. C. Nossent, “Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms?” *Arthritis & Rheumatism*, vol. 48, no. 2, pp. 300–312, 2003.

[25] M. Benucci, G. Saviola, P. Baiardi, E. Cammelli, and M. Manfredi, “Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis,” *Clinical Rheumatology*, vol. 27, no. 1, pp. 91–95, 2008.

[26] A. Sawada and M. Inoue, “Hematopoietic stem cell transplantation for the treatment of Epstein-Barr virus-associated T- or NK-Cell lymphoproliferative diseases and associated disorders,” *Frontiers in Pediatrics*, vol. 6, pp. 1–9, 2018.

[27] K. F. Hui, S. P. T. Yiu, K. P. Tam, and A. K. S. Chiang, “Viral-targeted strategies against EBV-associated lymphoproliferative diseases,” *Frontiers in Oncology*, vol. 9, pp. 1–18, 2019.